Up­dat­ed: No­vo Nordisk's semaglu­tide in­jec­tion re­duces car­dio­vas­cu­lar events by 20% in vast SE­LECT tri­al

No­vo Nordisk’s semaglu­tide in­jec­tion re­duced ma­jor ad­verse car­dio­vas­cu­lar events by 20% in obese or over­weight pa­tients with­out di­a­betes, fur­ther bol­ster­ing the case for more wide­spread …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER